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Introduction
Preeclampsia is one of the major causes of mortality in
pregnant women. Excluding ethnic factors, the incidence
of preeclampsia is about 5% globally. From 1974 to
1985, the incidence of preeclampsia in Taiwan was
2.06%, but preeclampsia has been implicated as the
cause of 23.7% perinatal maternal deaths [1]. Unfor-
tunately, the cause of preeclampsia remains unclear to
date. Preeclampsia is associated with abnormal pla-
centation, reduced placental perfusion, and systemic
vasospasm. Vascular and hemostatic hyperreactivities
involving the renin–angiotensin system, eicosanoids, and
platelets have all been implicated.
Several reports have demonstrated, through human
and animal studies, the association of androgens, espe-
cially testosterone, with hypertension. Baker et al pointed
out that women with polycystic ovary disease, a disease
associated with hyperandrogenemia, are at increased
risk of pregnancy-induced hypertension [2]. Recent stud-
ies have shown that androgens have important effects
on vascular reactivity, the renin–angiotensin system,
eicosanoids, and platelets.
Androgens, i.e. testosterone and androstenedione,
are produced in the ovarian thecal cells. In addition, a
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SUMMARY
Objective: To elucidate the expression of androgen receptor (AR) in human placenta from normal and preeclamptic
(PE) pregnancies.
Materials and Methods: This study was performed at the Division of Obstetrics and Gynecology, Kaohsiung
Chang Gung Memorial Hospital, Academic Medical Center. Forty normal pregnant women at 37.0 ± 0.89
weeks’ gestation and 40 women with preeclampsia at 35.9 ± 1.33 weeks’ gestation were included in this study.
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Results: Women with preeclampsia had an elevated serum testosterone level (0.52 ± 0.13 vs. 0.34 ± 0.11 ng/mL;
p < 0.01). The expression of AR in both placentas was confirmed using immunohistochemistry and was primarily
present in the nucleus and cytoplasm of syncytiotrophoblasts and stromal cells. There was a significant increase
in AR mRNA expression in PE placentas compared with normal placentas.
Conclusion: These data suggest that the increased AR expression may alter AR-mediated function on syncytiotro-
phoblasts and stromal cells in PE placentas, and be a possible mechanism for its association with preeclampsia.
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local factor, inhibin, within the follicles was recently
shown to increase androgen production by thecal cells,
which in turn increased circulating androgen levels in
women. The serum concentrations of inhibin A and the
potent androgen testosterone were higher in patients
with preeclampsia than in matched control subjects
with normal pregnancies [3,4]. It is possible that the
effects of increased serum inhibin in preeclampsia may
be manifested through increased circulating androgen
levels.
Women with prior preeclampsia have elevated serum-
free testosterone levels and free androgen index [5].
Acromite et al [6] reported that levels of the potent
androgen testosterone were significantly higher in pri-
migravid women with preeclampsia than in normoten-
sive women at similar gestational and maternal ages.
Serin et al [7] found that testosterone and free testos-
terone levels were found to be significantly higher in
preeclamptic (PE) women in the third trimester compared
with the values in normotensive controls. They concluded
that higher blood androgen levels measured in PE patients
may be implicated in the pathogenesis of preeclampsia.
Several studies have shown that androgen can cause
physiologic changes strikingly similar to those seen in
preeclampsia. Androgens also decrease prostacyclin
production in vitro and increase production of other
eicosanoids (including thromboxane), resulting in a
thromboxane/prostacyclin ratio that favors vascular
constriction and coagulation in a way similar to that
seen in preeclampsia [8]. As normal pregnancy pro-
gresses and the placenta grows, androgens tend to
decline and estrogens tend to increase as a result of
increased placental enzyme activity. Hahnel et al [9]
showed that pregnancies complicated by hypertension
have a deficiency in placental aromatization enzymes,
which may lead to high levels of androgens, including
testosterone.
It is possible that androgens may play a mediating or
amplifying role in the pathophysiology of preeclampsia.
However, the relationship between androgen and the
placental androgen receptor (AR) in PE pregnancy is
unclear. The purpose of our study was to compare the
expression of placental AR between normal and PE
pregnancies.
Materials and Methods
In this prospective, controlled, cross-sectional study, we
evaluated 80 women with singleton pregnancies who
received perinatal care from August 2001 to January
2002 at the Division of Obstetrics and Gynecology,
Kaohsiung Chang Gung Memorial Hospital, a tertiary
clinical care center. All women included in this study
gave informed consent. Blood samples were obtained
from peripheral blood taken from 40 pregnant women
with preeclampsia and 40 healthy, gestational age-
matched pregnant women. Samples were centrifuged
at 3,000 rpm for 15 minutes, and serum was stored in
microtubes at −80°C  until assayed.
Preeclampsia was defined as new onset hypertension
after 20 weeks’ gestation with systolic blood pressure
> 140 mmHg, diastolic pressure > 90 mmHg, or both,
measured on two occasions > 6 hours apart, and sig-
nificant proteinuria (300mg per 24 hours). No subject
had a history of hypertension or renal disease. Control
subjects were apparently healthy and without hyperten-
sion and proteinuria. Immunochemical staining was
performed on the placentas from both groups. Twelve
women were selected randomly from among the 40 PE
women, and 15 gestational age-matched subjects were
then selected randomly from the 40 control subjects. We
performed real-time quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis on placen-
tas from 12 PE patients and 15 normal pregnant women.
Androgen assay
Non-fasting serum samples were drawn at a non-
standardized time of the day, centrifuged at room
temperature and stored at −80°C until assay. Total
testosterone was measured by means of a commercially
available radioimmunoassay, using a sensitive and spe-
cific rabbit anti-human testosterone antibody (Diagnos-
tic Products Corp., Webster, TX, USA). Mean intra-assay
coefficients of variation (CV) of the assays were 7.7, 8.1
and 6.7% at 0.52, 5.05 and 13.77 ng/mL, respectively
(n = 14). Mean interassay CV were 10.5, 5.7 and 8.1% at
0.57, 6.00 and 13.62 ng/mL, respectively (n = 11).
Immunohistochemical stain
Placental specimens were fixed with paraformaldehyde
and embedded in paraffin, and immunohistochemistry
was performed on 4-μm sections using the Vectastain
Elite ABC kit (Vector Laboratories, Burlingame, CA,
USA). Tissue sections were deparaffinized in xylene,
dehydrated in a graded series of ethanol. Following a
phosphate buffered saline (PBS) rinse, the endogenous
peroxidases were quenched on incubation for 15 min-
utes with 3% H2O2 in absolute ethanol followed by a
10-minute rehydration in PBS. The tissue sections for AR
determination were heated in a microwave for 14 min-
utes in antigen retrieval solution (10 mM citrate buffer)
before incubation with primary antibody. After initial
incubation with blocking serum for 30 minutes at room
temperature, rabbit polyclonal antibody raised against
AR (N-20, sc-816; Santa Cruz Biotechnology, Inc., Santa
Taiwan J Obstet Gynecol • September 2009 • Vol 48 • No 3264
T.Y. Hsu, et al
Cruz, CA, USA) was applied at a concentration of 4 μg/
mL and 1:200. Finally, sections were counterstained with
hematoxylin, dehydrated in a graded series of ethanol,
cleared with xylene, mounted in Permount, and coverslips
placed over for evaluation by light microscopy.
Placental tissue collection, RNA extraction, and 
cDNA preparation
Specimens (0.25 g) of human placentas were collected
from PE pregnant women (n = 12) and normotensive
pregnant women (n = 15). They were washed with PBS
solution, and resuspended in guanidine isothiocyanate
buffer with β-mercaptoethanol then stored at −80°C.
Total RNA was extracted from placental tissue by Trizol
reagent (Invitrogen, Grand Island, NY, USA). Briefly,
1 mL of Trizol was added to the placental tissue. The
mixture was pipetted to agitate and allowed to sit for 
5 minutes at room temperature. Chloroform (0.2 mL)
was added, mixed, and allowed to incubate at room
temperature for 3 minutes. The mixture was centrifuged
at 12,000g for 15 minutes, and the supernatant was
transferred to a fresh tube. Isopropanol (0.5 mL) was
added, mixed, and incubated for 10 minutes at room
temperature. The solution was processed by centrifuge
at 12,000g for 10 minutes, and the RNA was purified.
The pellet was washed once with 70% ethanol, resus-
pended in water, and stored at −80°C. The quality of the
RNA samples was determined by electrophoresis through
agarose gels and staining with ethidium bromide.
Total RNA (2 μg) from the sample preparation was
reverse transcribed in 25μL as follows: 0.1μg of random
hexamer primers (Amersham Pharmacia Biotech, Inc.,
Buckinghamshire, UK) were denatured for 10 minutes
at 70°C in a gradient cycler (DNA Engine; MJ Research,
Watertown, MA, USA). The subsequent reverse tran-
scription was done at 42°C for 1 hour by adding 5X
reverse transcriptase buffer (500 mM each deoxynu-
cleotide triphosphate [dNTP], 3 mM MgCl2, 2.75 mM
KCl, and 50 mM Tris-HCl [pH 8.3]), 1 mM dNTP
(Promega, Madison, WI, USA), 10 IU of ribonuclease
inhibitor (Promega), and 100 U of Moloney murine
leukemia virus reverse transcriptase (Promega). The
reverse transcriptase was inactivated by heating at
95°C for 5 minutes and cooling at 4°C for 5 minutes.
Real-time quantitative RT-PCR analysis
Preparation of real-time PCR mix
All PCR reactions were performed with an ABI Prism
7900 Sequence Detection System (Perkin Elmer–Applied
Biosystems, Courtaboeuf, France). PCR was performed
using the SYBR Green PCR Core Reagents Kit (Perkin
Elmer–Applied Biosystems). The amplification reactions
were performed in a 50-μL final volume containing
10X SYBR Green buffer, 3 mM MgCl2, 2.5 mM dNTP,
1.25 U of Taq-Gold, 0.25 U of reverse transcriptase,
0.4 U ribonuclease inhibitor, 10 μL RNA. Final AR (for-
ward primer sequence: CCT ggC TTC CgC AAC TTA
CAC; reverse primer sequence: ggA CTT gTg CAT gCg
gTA CTC A) and β-actin (forward primer sequence:
TCA CCC ACA CTg TgC CCA TCT ACg A; reverse
primer sequence: CAg Cgg AAC CgC TCA TTg CCA
ATg g) forward and reverse primer concentrations
were 0.4 μM. To reduce the variability between repli-
cates, PCR premixes which contained all the reagents
expected to be used for the cDNA were prepared and
aliquoted into 1.5-mL microfuge tubes. Experiments
were performed with duplicates for each data point.
Real-time RT-PCR time and temperature profiles
The real-time RT-PCR protocol used for AR was as 
follows: denatured program (60°C for 10 minutes,
95°C for 10 minutes), amplification and quantifica-
tion program repeated 40 times (95°C for 20 seconds,
65oC for 30 seconds, 72°C for 30 seconds), and melting
curve program (95°C for 15 seconds, 60°C to 95°C
with a heating rate of 0.2°C per second).
Calibration curves
All samples with threshold cycle (Ct) CV values higher
than 1% were retested. The quantity of AR mRNA was
calculated using the Ct method. Briefly, the fluores-
cence signal threshold was defined such that each PCR
reaction was in the exponential phase. The Ct value
was the cycle at which the fluorescence signal of the
reaction exceeded this value. Ct values were propor-
tional to the starting copy number (using the Perkin
Elmer–Applied Biosystems analysis software), accord-
ing to the manufacturer’s manual.
Ct values of the AR target gene were normalized 
to the Ct value of a housekeeping gene, β-actin. The
precise amount of total RNA added to each reaction
(based on absorbance) and its quality (i.e. lack of exten-
sive degradation) were both difficult to assess. We,
therefore, also quantified transcripts of the gene β-actin
as the endogenous RNA control, and each sample was
normalized on the basis of its β-actin content. Results
are presented as: 2Ct, where Ct = Ctβ-actin − Cttarget gene.
Statistical analysis
The SigmaStat  9.0 statistical package (Jandel Corpora-
tion, San Rafael, CA, USA) was used for data analysis.
All p values were two-sided, and a p value of < 0.05 was
considered statistically significant. The nonparametric
Mann-Whitney U test (StatView 1996; Abacus Concepts,
Inc., Berkeley, CA, USA) was used to evaluate the varia-
tion in expression between human placental tissues.
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Results
The clinical characteristics of the PE and normal preg-
nancy women were comparable and matched by mater-
nal age and gestational age. The birth weight was greater
in the normal pregnancy group. The systolic and dias-
tolic blood pressures were higher in the PE pregnancy
group. PE women were characterized by elevated serum
testosterone levels (p < 0.01; Table 1).The microscopic
examination of PE placentas showed small-sized villi
with many syncytial knots and focal perivillous and
intervillous fibrinoids. Focal calcification and necrosis
were noted at the edge of the placenta. Syncytiotro-
phoblasts and stromal cells in human placentas were
positive for the AR with nuclear and cytoplasmic stain-
ing (Figure). The AR mRNA levels were presented as 
Table 1. Patient characteristics*
Preeclamptic women Normal pregnant women
p
(n = 40) (n = 40)
Gestational age (yr) 29.6 ± 5.0 28.7 ± 4.4 NS
Gestational week (wk) 35.9 ± 1.33 37.0 ± 0.89 NS
Body weight (g) 1,822.0 ± 726.1 3,268.2 ± 368.8 < 0.01
Systolic blood pressure (mmHg) 179.4 ± 18.7 123.0 ± 8.5 < 0.01
Diastolic blood pressure (mmHg) 110.5 ± 11.5 77.6 ± 8.0 < 0.01
Serum testosterone (ng/mL) 0.52 ± 0.13 0.34 ± 0.11 < 0.01
*Data are expressed as mean ± standard deviation. NS = not significant.
Figure. Syncytiotrophoblasts and stromal cells are positive for androgen receptor with nuclear and cytoplasmic staining.
Androgen receptor distribution is illustrated for (A, C) normal specimens and for (B, D) preeclampsia specimens. (A, B)
Original magnification × 200; (C, D) original magnification × 400.
A B
C D
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a ratio between the target gene and a reference gene
(β-actin) to correct for variation in the amounts of
RNA. There was significantly increased mRNA expres-
sion of AR in PE placentas compared with that in normal
placentas (Table 2).
Discussion
Androgens are synthesized and secreted into the blood-
stream for circulation largely as a form of testosterone,
which enters its target cells before it can exert its spe-
cific function. Patients with polycystic ovarian disease,
a syndrome with hyperandrogenism, have a higher risk
of developing preeclampsia. The association of pre-
eclampsia and polycystic ovarian disease supports a
relationship with androgens. Several studies demon-
strated that the levels of androgen were significantly
higher in women with preeclampsia than in normoten-
sive women with similar body mass index, gestational
age, and chronologic age [7]. Two in vitro studies showed
reduced conversion of androgens to estrogens in pla-
cental tissue from PE pregnancies. Accordingly, several
studies have consistently supported the important role
of androgens in the development of arterial hyperten-
sion. Our results support previous studies which found
elevated serum testosterone levels in PE women.
The AR is a member of the steroid hormone recep-
tor family, which is found in a variety of tissues, and
changes throughout development, aging, and malig-
nant transformation. A concomitant increase in both
serum androgens and elevations in endometrial ARs 
in women with polycystic ovarian syndrome has been
reported [10]. ARs could be demonstrated in the decid-
uas and trophoblastic cells from three first-trimester
human samples using immunohistochemistry [11].
However, the study of Chan et al [12] showed the
absence of ARs in all samples from human first-trimester
placenta and deciduas. These observations indicated
that there is little AR expression in early human pla-
centa and deciduas. Our study showed that the positive
staining of ARs was observed primarily in the nucleus
and cytoplasm of syncytiotrophoblast and stromal cells
in human placentas. To our knowledge, for the first time,
we demonstrated that the AR is expressed in normal
and PE placentas at near-term pregnancy. Several pre-
vious reports have shown that AR levels in Sertoli cells
are more sensitive to androgen regulation in adult as
compared with those in immature animals. According
to our findings, we hypothesize that the greater the
gestational age, the higher is the expression of AR in
human placentas.
Here, we also found that AR expression was signifi-
cantly increased in PE placentas compared with normal
placentas. Recently, several reports pointed out that
androgens induce a variety of effects on blood vessels.
Testosterone induces endothelium-independent vasodi-
lation [13]; conversely, it can act via the endothelium to
oppose relaxation and produce vasoconstriction [14].
The latter action varies according to gender, being
more marked in men, a fact that may contribute to the
increased risk of vascular events in men [15]. Increasing
evidence suggests possible adverse effects of androgens
on the vasculature. In vitro studies suggest that andro-
gens may directly accelerate atherosclerosis by stimu-
lating the proliferation of vascular smooth muscle cells
[16]. Ling et al [17] showed that testosterone, but not
dehydroepiandrosterone or estradiol, at physiologic
concentrations, enhances apoptosis-related damage in
human vascular endothelial cells after serum deprivation.
It has been reported in the past that androgens can
cause physiologic changes strikingly similar to those
seen in preeclampsia. Androgens also decrease prosta-
cyclin production in vitro and increase production of
other eicosanoids (including thromboxane), resulting
in a thromboxane to prostacyclin ratio which favors
vascular constriction and coagulation in a way similar
to that seen in preeclampsia.
At the cellular level, increased androgen bioactivity
may result from elevated circulating androgen concen-
trations and/or increased AR transactivational activity
which are influenced by the AR gene. Only limited infor-
mation is available regarding the possible involvement
of arterial ARs in atherogenesis processes. Hanke et al
[18] first showed an upregulation of the expression of
arterial AR mRNA with testosterone; they hypothesized
that vascular ARs might play an important role in sig-
naling of the testosterone effects at the level of the arte-
rial vessel wall. This “total androgen bioactivity” might
contribute to the risk of preeclampsia. In the future,
further evaluation of their biologic actions in PE pla-
centas will undoubtedly contribute to our understanding
of androgen effects in preeclampsia.
In conclusion, this study demonstrated that the AR
is expressed in normal and PE placentas in near-term
and term pregnancy. In addition, there is a significant
Table 2. Androgen receptor (AR) expression levels are 
displayed as a ratio between the target gene and a 
reference gene (β-actin) to correct for variation in the 
amounts of RNA
Normal Preeclampsia
p*
(n = 15) (n = 12)
AR:β-actin 3.7 ± 1.8 36.8 ± 19.0 < 0.001
*Mann-Whitney U test.
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increase in AR mRNA expression in PE placentas com-
pared with that in normal placentas. Further study 
of the AR gene and its influence is important in the
future.
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